KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Current Deferred Revenue: 2010-2025

Historic Current Deferred Revenue for Rigel Pharmaceuticals (RIGL) over the last 13 years, with Sep 2025 value amounting to $1.4 million.

  • Rigel Pharmaceuticals' Current Deferred Revenue changed negligibly% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $1.4 million for FY2024, which is negligibly% changed negligibly from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Current Deferred Revenue of $1.4 million as of Q3 2025, which was down 0.00% from $1.4 million recorded in Q2 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Current Deferred Revenue peaked at $9.5 million during Q1 2021, and registered a low of $1.4 million during Q2 2023.
  • For the 3-year period, Rigel Pharmaceuticals' Current Deferred Revenue averaged around $1.4 million, with its median value being $1.4 million (2025).
  • In the last 5 years, Rigel Pharmaceuticals' Current Deferred Revenue surged by 362.74% in 2021 and then slumped by 77.93% in 2022.
  • Rigel Pharmaceuticals' Current Deferred Revenue (Quarterly) stood at $2.6 million in 2021, then slumped by 47.27% to $1.4 million in 2022, then declined by 1.02% to $1.4 million in 2023, then remained steady at $1.4 million in 2024, then remained steady at $1.4 million in 2025.
  • Its Current Deferred Revenue stands at $1.4 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.4 million for Q1 2025.